Laurus Labs announced that it has completed the US Food and Drug Administration (USFDA) inspection of its API facilities in Units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations which are procedural in nature.
This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
